Refractory Diarrhea-Predominant IBS: Three Drugs, Three Different Failure Modes
A single patient with diarrhea-predominant irritable bowel syndrome refractory to first-line therapy, comparing rifaximin retreatment, eluxadoline, and alosetron against the specific reason each prior option failed her.
Yolanda C., a 44-year-old woman who manages a restaurant, has lived with diarrhea-predominant IBS for nearly a decade, but the last year has been the worst stretch yet — urgent, unpredictable diarrhea that's made her afraid to commit to the dinner-rush shifts she used to run without a second thought, and a quality of life she describes flatly as "planning my whole day around where the bathroom is." She tried a course of rifaximin eight months ago with a real but partial response — meaningfully better for about six weeks before her symptoms crept back toward baseline — and had her gallbladder removed two years ago for symptomatic cholelithiasis, a detail that turns out to matter more than it might seem to for what comes next.
Refractory IBS-D doesn't have one obvious next drug — it has three real options, each with a genuinely different mechanism and a genuinely different reason it might or might not fit her specifically. Rifaximin retreatment is a real possibility: TARGET 3, the trial that studied retreatment directly, enrolled patients with symptom recurrence after an initial response, which describes Yolanda's own course closely, and found retreatment effective and well-tolerated in that population. Eluxadoline works through a different mechanism entirely, a mixed mu- and kappa-opioid receptor agonist with delta-opioid receptor antagonism that slows transit and reduces visceral sensitivity — and it is the drug whose symptom profile fits her best. It is also the one she cannot have. Its label does not carry a boxed warning; it carries something stronger, an outright contraindication in patients without a gallbladder, added after the FDA collected reports of serious and fatal pancreatitis concentrated in cholecystectomy patients, some occurring after a single dose. Her cholecystectomy two years ago is not a risk factor to weigh against her symptom fit — it is the exclusion criterion itself. Alosetron, a 5-HT3 receptor antagonist, is real and effective for severe IBS-D but was withdrawn from the market in 2000 for ischemic colitis and serious complications of constipation, then reintroduced in 2002 under a restricted prescribing program. That program no longer exists: the FDA relaxed it in 2016 and eliminated the REMS entirely in September 2023, after its own Sentinel analysis found the ischemic colitis rate in new female users consistent with the figure already printed on the label. What survived is the boxed warning and a labeled indication still confined to women with severe IBS-D who have not responded to conventional therapy — which is a description of Yolanda rather than a hurdle she has to clear.
Clinic, choosing among three refractory-IBS-D options
I'd retreat with rifaximin first. She had a genuine, if partial, response to her first course — meaningful improvement for about six weeks before symptoms recurred, which is a real signal she's the kind of patient TARGET 3 actually studied, patients with symptom recurrence after an initial response. That trial found retreatment effective and well-tolerated in exactly that population, and a partial responder is mechanistically a better retreatment candidate than someone who never responded to the drug at all.
Before this goes further, I want to flag something that isn't a preference, it's a hard stop: eluxadoline is contraindicated in patients without a gallbladder. Not a boxed warning — people misremember it that way — a contraindication, which is the stronger instrument. Yolanda had a cholecystectomy two years ago. Whatever else might otherwise recommend eluxadoline for her symptom pattern, that fact takes it off the table entirely: this isn't a risk to weigh, it's a population the drug's own label excludes.
Given that, I'd want rifaximin retreatment tried first, as proposed, but I'd name alosetron now rather than only after a second rifaximin failure — and I'd correct one thing, because it changes what we have to do today. There's no program to enroll in anymore. The REMS was eliminated in 2023 once the FDA's own data showed the ischemic colitis rate matching the label. The boxed warning is unchanged and so is the labeled population, which still reads: women with severe diarrhea-predominant IBS who haven't responded adequately to conventional therapy. That's a description of Yolanda. So there's no paperwork to start — there's a conversation to have, and it's on us to have it properly rather than on a program to make us.
Agreed: rifaximin retreatment started now, with the alosetron risk-counseling process begun in parallel rather than sequentially, so no additional delay accrues if a second course doesn't hold. Eluxadoline was removed from consideration entirely and documented in the chart as contraindicated given her cholecystectomy, not simply deprioritized, so the question doesn't quietly resurface at a future visit without that history being rechecked.